Preferred Label : Allogeneic Anti-CD70 CAR/dnTGF-BRII-expressing Gamma Delta T-cells ADI-270;
NCIt synonyms : Allogeneic Anti-CD70 Gamma-delta CAR T Cells ADI-270; Allogeneic Anti-CD70 Gamma-delta CAR-T Cells ADI-270;
NCIt definition : A preparation of allogeneic Vdelta1 gamma delta T-lymphocytes engineered to express
a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human
cluster of differentiation 70 (CD70) and a dominant negative (dn) form of transforming
growth factor-beta (TGF-beta; TGFb) receptor II (dnTGF-BRII), with potential immunostimulating
and antineoplastic activities. Upon administration, allogeneic anti-CD70 CAR/dnTGF-BRII-expressing
gamma delta T-cells ADI-270 recognize and bind to CD70-expressing tumor cells. This
may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD70-positive
tumor cells. CD70, a type II transmembrane glycoprotein and member of the tumor necrosis
factor (TNF) family, is found on the surfaces of various types of cancer cells. The
inclusion of dnTGF-BRII blocks the signaling of the immunosuppressive cytokine TGFb
in the tumor microenvironment (TME) and makes the ADI-270 T-cells resistant to TGFb.
TGFb negatively regulates T-cell proliferation and activation and plays a key role
in tumor immune suppression. Gamma delta T-lymphocytes play a key role in the activation
of the immune system and do not require major histocompatibility complex (MHC)-mediated
antigen presentation to exert their cytotoxic effect.;
Molecule name : ADI 270; ADI-270;
Origin ID : C212213;
concept_is_in_subset
- has_target
